Top

Published in:

01-06-2017

Effects of cognitive behavioral therapy for insomnia and armodafinil on quality of life in cancer survivors: a randomized placebo-controlled trial

Authors: Anita R. Peoples, Sheila N. Garland, Michael L. Perlis, Josée Savard, Charles E. Heckler, Charles S. Kamen, Julie L. Ryan, Karen M. Mustian, Michelle C. Janelsins, Luke J. Peppone, Gary R. Morrow, Joseph A. Roscoe

Published in: Journal of Cancer Survivorship | Issue 3/2017

Abstract

Purpose

Cancer-related insomnia is associated with diminished quality of life (QOL), suggesting that improvement in insomnia may improve QOL in cancer survivors. Cognitive behavioral therapy for insomnia (CBT-I) has been shown to improve insomnia, but less is known regarding its effect on QOL and whether improvement in insomnia corresponds to improved QOL. The present analysis examines the effects of CBT-I, with and without armodafinil, on QOL both directly and indirectly through improvements of insomnia.

Methods

This is an analysis of 95 cancer survivors for a specified secondary aim of a four-arm randomized controlled trial assessing the combined and individual effects of CBT-I and armodafinil to improve insomnia. QOL and insomnia severity were assessed before, during the intervention, at post-intervention, and 3 months later by Functional Assessment of Cancer Therapy—General and Insomnia Severity Index, respectively.

Results

Mean change in QOL from pre- to post-intervention for CBT-I + placebo, CBT-I + armodafinil, armodafinil, and placebo was 9.6 (SE = 1.8; p < 0.0001), 11.6 (SE = 1.8; p < 0.0001), −0.2 (SE = 3.2; p = 0.964), and 3.3 (SE = 2.0; p = 0.124), respectively. ANCOVA controlling for pre-intervention scores showed that participants receiving CBT-I had significantly improved QOL at post-intervention compared to those not receiving CBT-I (p < 0.0001, effect size = 0.57), with benefits being maintained at the 3-month follow-up. Path analysis revealed that this improvement in QOL was due to improvement in insomnia severity (p = 0.002), and Pearson correlations showed that changes in QOL from pre- to post-intervention were significantly associated with concurrent changes in insomnia severity (r = −0.56; p < 0.0001). Armodafinil had no effect on QOL for those who did or did not receive it (p = 0.976; effect size = −0.004).

Conclusion

In cancer survivors with insomnia, CBT-I resulted in clinically significant improvement in QOL via improvement in insomnia. This improvement in QOL remained stable even 3 months after completing CBT-I.

Implications for Cancer Survivors

Considering the high prevalence of insomnia and its detrimental impact on QOL in cancer survivors and the effectiveness of CBT-I in alleviating insomnia, it is important that evidence-based non-pharmacological sleep interventions such as CBT-I be provided as an integral part of cancer care.

American Cancer Society. Cancer treatment & survivorship facts & figures 2016–2017. Atlanta: American Cancer Society; 2016.

Hewitt M, Rowland JH, Yancik R. Cancer survivors in the United States: age, health, and disability. J Gerontol A Biol Sci Med Sci. 2003;58(1):82–91.CrossRefPubMed

Cella DF, Tulsky DS. Quality of life in cancer: definition, purpose, and method of measurement. Cancer Investig. 1993;11(3):327–36.CrossRef

Trentham-Dietz A, Sprague BL, Klein R, Klein BE, Cruickshanks KJ, Fryback DG, et al. Health-related quality of life before and after a breast cancer diagnosis. Breast Cancer Res Treat. 2008;109(2):379–87. doi:10.1007/s10549-007-9653-1.CrossRefPubMed

Pockaj BA, Degnim AC, Boughey JC, Gray RJ, McLaughlin SA, Dueck AC, et al. Quality of life after breast cancer surgery: what have we learned and where should we go next? J Surg Oncol. 2009;99(7):447–55. doi:10.1002/jso.21151.CrossRefPubMed

Weaver KE, Forsythe LP, Reeve BB, Alfano CM, Rodriguez JL, Sabatino SA, et al. Mental and physical health-related quality of life among U.S. cancer survivors: population estimates from the 2010 National Health Interview Survey. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012;21(11):2108–17. doi:10.1158/1055-9965.EPI-12-0740.CrossRef

Liu L, Fiorentino L, Rissling M, Natarajan L, Parker BA, Dimsdale JE, et al. Decreased health-related quality of life in women with breast cancer is associated with poor sleep. Behav Sleep Med. 2013;11(3):189–206. doi:10.1080/15402002.2012.660589.CrossRefPubMed

Lis CG, Gupta D, Grutsch JF. The relationship between insomnia and patient satisfaction with quality of life in cancer. Support Care Cancer. 2008;16(3):261–6. doi:10.1007/s00520-007-0314-z.CrossRefPubMed

Fortner BV, Stepanski EJ, Wang SC, Kasprowicz S, Durrence HH. Sleep and quality of life in breast cancer patients. J Pain Symptom Manag. 2002;24(5):471–80.CrossRef

10.

Clevenger L, Schrepf A, Degeest K, Bender D, Goodheart M, Ahmed A, et al. Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer. 2013;119(17):3234–41. doi:10.1002/cncr.28188.CrossRefPubMedPubMedCentral

11.

Fiorentino L, Ancoli-Israel S. Insomnia and its treatment in women with breast cancer. Sleep Med Rev. 2006;10(6):419–29. doi:10.1016/j.smrv.2006.03.005.CrossRefPubMedPubMedCentral

12.

Savard J, Villa J, Ivers H, Simard S, Morin CM. Prevalence, natural course, and risk factors of insomnia comorbid with cancer over a 2-month period. J Clin Oncol. 2009;27(31):5233–9. doi:10.1200/JCO.2008.21.6333.CrossRefPubMed

13.

Savard J, Simard S, Blanchet J, Ivers H, Morin CM. Prevalence, clinical characteristics, and risk factors for insomnia in the context of breast cancer. Sleep. 2001;24(5):583–90.CrossRefPubMed

14.

Davidson JR, MacLean AW, Brundage MD, Schulze K. Sleep disturbance in cancer patients. Soc Sci Med. 2002;54(9):1309–21.CrossRefPubMed

15.

Savard J, Ivers H, Villa J, Caplette-Gingras A, Morin CM. Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. J Clin Oncol. 2011;29(26):3580–6. doi:10.1200/JCO.2010.33.2247.CrossRefPubMed

16.

Gooneratne NS, Dean GE, Rogers AE, Nkwuo JE, Coyne JC, Kaiser LR. Sleep and quality of life in long-term lung cancer survivors. Lung Cancer. 2007;58(3):403–10. doi:10.1016/j.lungcan.2007.07.011.CrossRefPubMedPubMedCentral

17.

Dickerson SS, Connors LM, Fayad A, Dean GE. Sleep-wake disturbances in cancer patients: narrative review of literature focusing on improving quality of life outcomes. Nat Sci Sleep. 2014;6:85–100. doi:10.2147/NSS.S34846.CrossRefPubMedPubMedCentral

18.

Garland SN, Johnson JA, Savard J, Gehrman P, Perlis M, Carlson L, et al. Sleeping well with cancer: a systematic review of cognitive behavioral therapy for insomnia in cancer patients. Neuropsychiatr Dis Treat. 2014;10:1113–24. doi:10.2147/NDT.S47790.PubMedPubMedCentral

19.

Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: sleep and psychological effects. J Clin Oncol. 2005;23(25):6083–96. doi:10.1200/JCO.2005.09.548.CrossRefPubMed

20.

Espie CA, Fleming L, Cassidy J, Samuel L, Taylor LM, White CA, et al. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol. 2008;26(28):4651–8. doi:10.1200/JCO.2007.13.9006.CrossRefPubMed

21.

Matthews EE, Berger AM, Schmiege SJ, Cook PF, McCarthy MS, Moore CM, et al. Cognitive behavioral therapy for insomnia outcomes in women after primary breast cancer treatment: a randomized, controlled trial. Oncol Nurs Forum. 2014;41(3):241–53. doi:10.1188/14.ONF.41-03AP.CrossRefPubMed

22.

Garland SN, Carlson LE, Stephens AJ, Antle MC, Samuels C, Campbell TS. Mindfulness-based stress reduction compared with cognitive behavioral therapy for the treatment of insomnia comorbid with cancer: a randomized, partially blinded, noninferiority trial. J Clin Oncol. 2014;32(5):449–57. doi:10.1200/JCO.2012.47.7265.CrossRefPubMed

23.

Davidson JR, Feldman-Stewart D, Brennenstuhl S, Ram S. How to provide insomnia interventions to people with cancer: insights from patients. Psychooncology. 2007;16(11):1028–38. doi:10.1002/pon.1183.CrossRefPubMed

24.

Perlis ML, Jungquist C, Smith MT, Posner D. Cognitive behavioral tretament of insomnia: a session-by-session guide. New York: Springer; 2005.

25.

National Institutes of H. National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13–15, 2005. Sleep. 2005;28(9):1049–57.

26.

Johnson JA, Rash JA, Campbell TS, Savard J, Gehrman PR, Perlis M, et al. A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors. Sleep Med Rev. 2016;27:20–8. doi:10.1016/j.smrv.2015.07.001.CrossRefPubMed

27.

Quesnel C, Savard J, Simard S, Ivers H, Morin CM. Efficacy of cognitive-behavioral therapy for insomnia in women treated for nonmetastatic breast cancer. J Consult Clin Psychol. 2003;71(1):189–200.CrossRefPubMed

28.

Dirksen SR, Epstein DR. Efficacy of an insomnia intervention on fatigue, mood and quality of life in breast cancer survivors. J Adv Nurs. 2008;61(6):664–75. doi:10.1111/j.1365-2648.2007.04560.x.CrossRefPubMed

29.

Savard J, Ivers H, Savard MH, Morin CM. Is a video-based cognitive behavioral therapy for insomnia as efficacious as a professionally administered treatment in breast cancer? Results of a randomized controlled trial. Sleep. 2014;37(8):1305–14. doi:10.5665/sleep.3918.CrossRefPubMedPubMedCentral

30.

Roscoe JA, Garland SN, Heckler CE, Perlis ML, Peoples AR, Shayne M, et al. Randomized placebo-controlled trial of cognitive behavioral therapy and armodafinil for insomnia after cancer treatment. J Clin Oncol. 2015;33(2):165–71. doi:10.1200/JCO.2014.57.6769.CrossRefPubMed

31.

Brucker PS, Yost K, Cashy J, Webster K, Cella D. General population and cancer patient norms for the Functional Assessment of Cancer Therapy-General (FACT-G). Eval Health Prof. 2005;28(2):192–211. doi:10.1177/0163278705275341.CrossRefPubMed

32.

Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manag. 2002;24(6):547–61.CrossRef

33.

Savard MH, Savard J, Simard S, Ivers H. Empirical validation of the Insomnia Severity Index in cancer patients. Psychooncology. 2005;14(6):429–41. doi:10.1002/pon.860.CrossRefPubMed

34.

Garland SN, Roscoe JA, Heckler CE, Barilla H, Gehrman P, Findley JC, et al. Effects of armodafinil and cognitive behavior therapy for insomnia on sleep continuity and daytime sleepiness in cancer survivors. Sleep Med. 2016;20:18–24. doi:10.1016/j.sleep.2015.12.010.CrossRefPubMed

35.

Heckler CE, Garland SN, Peoples AR, Perlis ML, Shayne M, Morrow GR, et al. Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: a randomized placebo-controlled trial. Support Care Cancer. 2016;24(5):2059–66. doi:10.1007/s00520-015-2996-y.CrossRefPubMed

36.

Ritterband LM, Bailey ET, Thorndike FP, Lord HR, Farrell-Carnahan L, Baum LD. Initial evaluation of an Internet intervention to improve the sleep of cancer survivors with insomnia. Psychooncology. 2012;21(7):695–705. doi:10.1002/pon.1969.CrossRefPubMed

37.

Pearman T, Yanez B, Peipert J, Wortman K, Beaumont J, Cella D. Ambulatory cancer and US general population reference values and cutoff scores for the functional assessment of cancer therapy. Cancer. 2014;120(18):2902–9. doi:10.1002/cncr.28758.CrossRefPubMed

38.

Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group. Neurology. 2000;54(5):1166–75.

39.

Perlis ML, Smith MT, Orff H, Enright T, Nowakowski S, Jungquist C, et al. The effects of modafinil and cognitive behavior therapy on sleep continuity in patients with primary insomnia. Sleep. 2004;27(4):715–25.CrossRefPubMed

40.

Lee EQ, Muzikansky A, Drappatz J, Kesari S, Wong ET, Fadul CE, et al. A randomized, placebo-controlled pilot trial of armodafinil for fatigue in patients with gliomas undergoing radiotherapy. Neuro-Oncology. 2016;18(6):849–54. doi:10.1093/neuonc/now007.CrossRefPubMed

41.

Spathis A, Fife K, Blackhall F, Dutton S, Bahadori R, Wharton R, et al. Modafinil for the treatment of fatigue in lung cancer: results of a placebo-controlled, double-blind, randomized trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(18):1882–8. doi:10.1200/JCO.2013.54.4346.CrossRef

42.

Berenson JR, Yellin O, Shamasunder HK, Chen CS, Charu V, Woliver TB, et al. A phase 3 trial of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma. Support Care Cancer. 2015;23(6):1503–12. doi:10.1007/s00520-014-2486-7.CrossRefPubMed

43.

Boele FW, Douw L, de Groot M, van Thuijl HF, Cleijne W, Heimans JJ, et al. The effect of modafinil on fatigue, cognitive functioning, and mood in primary brain tumor patients: a multicenter randomized controlled trial. Neuro-Oncology. 2013;15(10):1420–8. doi:10.1093/neuonc/not102.CrossRefPubMedPubMedCentral

Title: Effects of cognitive behavioral therapy for insomnia and armodafinil on quality of life in cancer survivors: a randomized placebo-controlled trial
Authors: Anita R. Peoples
Sheila N. Garland
Michael L. Perlis
Josée Savard
Charles E. Heckler
Charles S. Kamen
Julie L. Ryan
Karen M. Mustian
Michelle C. Janelsins
Luke J. Peppone
Gary R. Morrow
Joseph A. Roscoe
Publication date: 01-06-2017
Publisher: Springer US
Published in: Journal of Cancer Survivorship / Issue 3/2017
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI: https://doi.org/10.1007/s11764-017-0597-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Implications for Cancer Survivors

Please log in to get access to this content

Other articles of this Issue 3/2017

Toward the optimal strategy for sustained weight loss in overweight cancer survivors: a systematic review of the literature

Young adult cancer survivors’ follow-up care expectations of oncologists and primary care physicians

Evaluation of resistance training to improve muscular strength and body composition in cancer patients undergoing neoadjuvant and adjuvant therapy: a meta-analysis

The course of anxiety, depression and unmet needs in survivors of diffuse large B cell lymphoma and multiple myeloma in the early survivorship period

A dance intervention for cancer survivors and their partners (RHYTHM)

Health-related behaviors and mortality outcomes in women diagnosed with ductal carcinoma in situ

Keynote webinar | Spotlight on antibody–drug conjugates in cancer